top of page
RKenney Sep21.jpeg

Richard T. Kenney, MD, FACP

Chief Medical Officer

 

Dr. Kenney is the Chief Medical Officer at Sonnet BioTherapeutics and has more than 20 years of experience in translational-stage development of biologic products, as well as in the commercialization strategy and corporate management of preclinical, clinical-stage, and commercialized vaccines and immunotherapies. Dr. Kenney most recently served as Chief Development Officer at X-VAX Technology and previously held Chief Medical Officer roles at Immune Design and Crucell Holland, where he led the clinical development and regulatory affairs groups. Dr. Kenney was a researcher/reviewer for the FDA for over six years and did post-graduate training at Duke and NIH. He received a B.S. in Chemistry from George Washington University and his M.D. from Harvard Medical School.

 

IMG_2208.jpg 2.jpg

Joan Morris

Senior Medical Director

 

I am a pediatric oncologist/transplant physician with 25 years’ experience in various academic programs.  During my years in practice, I established and directed a FACT accredited pediatric stem cell transplant program and stem cell apheresis unit at Loma Linda University. I have publications in supportive care improvements for stem cell transplantation that have peer reviewed publications in Biology of Blood and Marrow Transplantation and Bone Marrow Transplant. In the past 8 years I have transitioned to a role in pharmaceutical development.  My initial pharmaceutical role was at Amgen where I helped in development of blinatumomab for leukemia and lymphoma.  This past year I joined AscendisPharm where I am working on the development of immune-oncology agents using TransCon Technology, an innovative oncology delivery platform, for the treatment of solid tumors.  

image.png

Philip A. Philip, M.D., Ph.D.

Director, Gastrointestinal Oncology

Co-Director, Pancreatic Cancer Center

Medical Director, Research and Clinical Care Integration, Henry Ford Cancer Institute

 

Philip A. Philip, M.D., Ph.D., is an internationally renowned medical oncologist specializing in gastrointestinal cancers. He has led numerous breakthroughs in the areas of pancreatic and neuroendocrine tumors. His depth of expertise in research and treatment is matched by his passion for team and personalized patient care.

Dr. Philip's extensive influence in various national and international arenas includes chairing the GI committee for SWOG (the NCI-sponsored clinical trials collaborative), serving on the NCI's Cancer Therapy Evaluation Program committee, authoring more than 200 publications, co-editing a book on pancreatic cancer and serving as an international/national lecturer with more than 400 presentations. He is an awarded professor at Wayne State University.

Syed Shah.jpg

Syed Shah, MD, MPH

Associate Director, Medical Monitoring at ClinChoice

Primary Care Physician with over 23 years of clinical research experience working in phase I-IV studies in pharmaceutical industry and CRO. During this time, Syed worked in different roles and held positions of responsibility including the Head of Regulatory, Deputy Affiliate Safety Officer, and Affiliate Quality Officer in pharmaceutical industry. 

 

Syed received his Master of Public Health (MPH) in Health Policy from University of North Carolina at Chapel Hill. Over 5 years of experience in first in human (FIH), phase I oncology studies

 

Syed possesses a keen ability for reading and comprehending complex clinical trial protocols. His experience in the field allows him to swiftly identify potential issues and operational challenges, enabling him to develop innovative solutions that enable seamless trial execution and compliance with regulatory standards. 

NASH10a-284x300-1.jpg

Nashat Y Gabrail M.D. –  Chief Executive Officer

Nash Gabrail, is the medical oncologist and founder of Gabrail Cancer Center. He is an author of 2 books, “Good Medicine is Cheaper Medicine” and “The Cancer Gene”. He is the host of 2 radio shows.

His resume is rich in 160 publications and abstracts in peer review journals. He is an avid clinical researcher who believes that clinical trials are the best option for every single cancer patient when available.

He is a graduate of Mosul Medical School in Iraq.  He completed graduate Internal Medicine education at The University of Edinburough, Scotland and Hematology/Oncology in Glasgow, Scotland. He opened the Gabrail Cancer Center in Canton, Ohio in 2005, which attracts patients for clinical trials nationally and internationally. He is a member of the Board of Directors and Trustee of the Ohio Hematology Oncology Society, a member of the Board of Advisors to National Oncology Network, a co-founder and Medical director of Employers Healthcare Savings (EHCS), past board member of Community Oncology Alliance (COA) and Clinical Associate Professor of Medicine at the Ohio Heritage College of Osteopathic Medicine.

His hobbies are golf and cooking.

Catalyst_June2021-71.jpg

Andrew Zupnick, PhD - Vice President, Oncology Drug Development

 

Andrew has focused exclusively in oncology for over 20 years and serves as the VP of Oncology Drug Development for Catalyst.  He is a cell & molecular biologist with a Ph.D. from Columbia University and a B.S. from MIT, and leads Catalyst’s full-service oncology solution, supporting study optimization, delivery oversight, training and new initiatives across the commercial and operational teams to keep Catalyst at the forefront of industry trends and cutting-edge oncology therapies.  Bringing a broad base of oncology experience to Catalyst, Andrew began his professional career at a niche oncology CRO, Prologue Research, which was founded out of what became the James Cancer Center at The Ohio State University and acquired in 2010 by Novella Clinical.  At Novella, Andrew led the growth of the organization’s oncology division into a market-leading oncology specialty CRO. After the acquisition of Novella by Quintiles, Andrew spent nearly seven years working within the standalone CRO which was subsequently rebranded to IQVIA Biotech in 2019.  Andrew enjoys a wide range of extracurricular activities from coaching a local travel baseball team (he played in college), cheering his son on who is a goalie for the AAA Blue Jackets (Andrew can’t skate), sneaking away for the occasional video game (he’s terrible at Fortnite), and being impressed by his daughter’s musical, dance and engineering talents (he can neither confirm nor deny the existence of some video of his a cappella group from college).  Andrew lives in Columbus, Ohio with his amazing wife Brooke and their 2 kids, where they enjoy family time, travel, and any game they can get their hands on.

IMG_0019-Krystyna Kowalczyk.jpg

Krystyna Kowalczyk - Chief Executive Officer at OncoBay Clinical

 

A global contract research organization (CRO) with a focus on complex oncology including immuno-oncology and cell therapy. With offices in Spain, Italy, Poland, India and the United States, she retains responsibility for the CRO’s strategic direction and performance across the globe and within all functions of the organization.

 

Ms. Kowalczyk, has over 30 years of clinical research operations and management experience in both large and small CROs and SMOs.  Her expertise and experience include developing strategic partnerships with pharma and biotech to drive innovation and development. In her leadership roles she has been responsible for evaluating and incorporating unique and innovative methodologies, platforms and concepts to accelerate and improve clinical development methods.

 

Prior to joining OncoBay, Ms. Kowalczyk was a founding member of Novella Clinical, an oncology-focused CRO and the first exclusively using electronic data capture. She continued implementing her creative vision by establishing Optimal Research, an oncology enrollment optimization engine leveraging the just-in-time model. She held the role of COO of the division from inception until acquisition by a top-tier CRO. Kowalczyk has overseen more than 200 clinical trials during her career.

headshot.jpeg

Jamie Oliver

 

Dr. Oliver’s drug development experience spans 12 years in academia and 28 years in both the public and private sectors of the biotechnology/pharmaceutical industry and contract research organizations serving in roles including Chief Executive Officer, Chief Medical Officer, Chief Science Officer, Chief Operating Officer, Managing Director European Operations, SVP Clinical Research and Regulatory Affairs, and Medical Affairs Officer.. He has an unparalleled background in clinical development having authored more than 50 INDs applications and participated in the clinical programs for 7 successful NDAs primarily in oncology. 

headshot, Taylor Walber full.jpeg

Taylor Walber

Global Sales, Clinical Solutions

 

Taylor is the Global Sales Lead for Slope's clinical software solutions, leveraging seven years of experience representing innovative medical device and software solutions in the healthcare and life sciences industry. Currently spearheading the adoption of Slope's transformative software for clinical trial execution, Taylor orchestrates go-to-market strategy for emerging, established, and enterprise pharmaceutical companies. With a passion for aligning cutting-edge technologies with unmet needs, Taylor is dedicated to reshaping the landscape of healthcare solutions to a future state where site and patient-centricity is the standard.

prof pic 2.png

Gardner Butterworth - Biotech Executive

 

Gardner is a successful biotech executive having helped take a 3D Bioprinting company from a start-up to a multi-billion dollar conglomerate. Gardner launched Trialist to solve the issues he faced in his previous life as a clinical research associate at CHB and CHOP. Having seen first hand the difficulty organizations face moving data to clients, be it Sponsors, AI, or RWE companies, Trialist automates the entire process and does the heavy lifting so Providers can focus on patients while improving margins and opening new streams of revenue to their practices. 

image001.png

Robert Morris, MD

I am a professor of gynecologic oncology, and my responsibilities include caring for patients with gynecologic malignancies, training residents and fellows, and advancing the knowledge in my field through research. I am well suited for participation and leadership in the research program because of my training, my research experience and production, as well as my contribution to education. In addition to two years of basic science post-graduate education at the University of Michigan and Wayne State University, I graduated from a very rigorous fellowship at the MD Anderson Cancer Center. I have been an institutional PI for over 50 studies at Wayne State University, and have been the PI on two investigator initiated multi-institutional clinical trials (1,2) As the director of Gynecologic Oncology, I am committed to overseeing the scientific efforts, the educational mission, and the medical management of patients with gynecologic malignancies. My research efforts include mentoring and directly participating with fellows in bench research as well as direct development, supervision, and participation in clinical research. In recognition of these qualifications and activities I have been a member of the Ovary Committee of the Gynecologic Oncology Group as well as contributed invited editorials from impactful journals (3)

Dr Vivek V. Abhyankar

 

currently serves as associate staff at Taussig Cancer Center, Cleveland Clinic Foundation in Amherst, OH. He is board certified in internal medicine and medical oncology and is a certified physician executive with the American Association of Physician Leaders.

 

Dr Abhyankar received his medical degree from Albany Medical College of Union University in New York and completed a residency in internal medicine and fellowship in hematology and oncology from The Ohio State University College of Medicine in Columbus, OH.

 

Dr Abhyankar has published several articles in peer-reviewed journals, and his work has been presented at national and international conferences, including the American Society of Clinical Oncology (ASCO) conference. He also received both the ASCO Merit Award and ASCO Young Investigator Award in 2002. He has served as a primary investigator/co-investigator for Phase 1, 2, and 3 oncology clinical trials.

image003.png
IMG_1212.jpeg

Carlton N. Sedberry, D.Ph.

Carlton’s diverse background includes over 35 years as a provider with a large community-oncology practice in Memphis, Tn., as a consultant for large community oncology practices, national oncology networks and bio/pharmaceutical manufacturers. During this time he held operational, business development and clinical roles at Response Oncology where he served as Executive VP of Development while creating a network of 55 multi-disciplined outpatient research centers in 32 states facilitating a national clinical trials initiative focused on high-dose chemotherapy with autologous stem cell support. As Executive VP of Strategic Development at CancerConsultants.com, Carlton developed a community oncology network of over 200 community-based practices and created a wide variety of digital custom oncology patient education content and community practice market research initiatives. He also has served as the Managing Director of two large state association sponsored community oncology-based GPO’s with over a billion dollars of combined purchases annually. For the past 15 years he has led pricing, reimbursement, market access and drug commercialization strategy initiatives for over 250 oncology indicated therapeutic agents as well as a wide range of oncology focused diagnostics and medical devices. 

 

He is currently working as National Accounts and Business Development lead for Electronic Medical Office Logistics (EMOL Health). 

 

Carlton holds a B.S. in Pharmaceutical Sciences and a Doctorate of Pharmacy from the University of Tennessee Center for Health Sciences School of Pharmacy.

Brady.Steineck.headshot.jpg

Brady Steineck, MD, MBA

 

A family physician and CEO of Community Health Care, Inc.  Brady grew up in northeast Ohio, and graduated medical school from NEOMED. After completing residency in Family Medicine at Aultman Hospital, he joined Community Health Care. He then completed an MBA in Healthcare Management at Walsh University and became CEO of Community Health Care in 2020.  Community Health Care is a national leader in value-based care and is an innovator in primary care operational models, patient experience and quality, and outcomes-based payment models.  Brady loves building long term relationships with his patients and enjoys practicing the full breadth of primary care. Brady lives in Canton and has been married to his wife Tiffany for 16 years. They have 5 children. 

bottom of page